Advanced Filters
noise

Immune Thrombocytopenia Clinical Trials

A listing of Immune Thrombocytopenia medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 88 clinical trials
H Haixia Fu, MD

Prednisone Plus IVIg vs. Prednisone for ITP During Pregnancy

This is a prospective, randomized, open-label, multicenter clinical trial study to compare the efficacy and safety of prednisone plus IVIg to prednisone monotherapy in the treatment of immune thrombocytopenia (ITP) in pregnancy.

18 - 50 years of age Female Phase 2

Inaticabtagene Autoleucel Injection in the Treatment of Refractory Systemic Lupus Erythematosus-related Immune Thrombocytopenia

This is a single-arm, open-label,phase I clinical study to evaluate the safety and tolerability of Inaticabtagene Autoleucel Injection in treatment of refractory systemic lupus erythematosus-related immune thrombocytopenia.

18 - 70 years of age All Phase 1
M Ming Hou, PhD

A Phase 1/2 Study of ESG206 in Patients With Primary Immune Thrombocytopenia

This is a multicenter, open-label Phase1/2 study aimed at evaluating the safety, tolerability, pharmacokinetic (PK) profile, pharmacodynamics (PD), immunogenicity, and preliminary efficacy of ESG206. The study will be conducted in patients with primary immune thrombocytopenia.

18 years of age All Phase 1/2
N Nuvig Clinical Trials

Safety, Tolerability, and Efficacy of NVG-2089 in Participants With Immune Thrombocytopenia

The purpose of the study is to evaluate the safety of NVG-2089 and to evaluate how well patients respond to this investigational treatment. NVG-2089 is a new drug that is being developed for treating patients with ITP. NVG-2089 is designed to mimic the effects of a protein called IVIg. NVG-2089 …

18 - 80 years of age All Phase 2
X Xingbing Wang

Anti CD19/BCMA CAR Gene Therapy for Relapsed/Refractory Immune Thrombocytopenia

This is an open label, single-site, dose-escalation study in up to 18 participants with treatment of relapsed and refractory immune thrombocytopenia. This study aims to evaluate the safety and efficacy of the treatment with an Anti- CD19/BCMA CAR gene vector injection

18 years of age All Phase N/A

Phase I Study of SHR-2173 Injection in Patients With Primary Immune Thrombocytopenia

Evaluate the safety and tolerance of multiple subcutaneous injections of SHR-2173 in ITP patients

18 years of age All Phase 1
Y Yunfei Chen, MD

A Prospective, One-arm and Open Clinical Study of Zanubrutinib in the Treatment of Immune Thrombocytopenia

To evaluate the safety and efficacy of zanubrutinib in the treatment of immune thrombocytopenia in 30 patients.

18 years of age All Phase 2
T Ting Sun, M.D

A Prospective, One-arm and Open Clinical Study of Obinutuzumab in the Treatment of Pediatric Primary Immune Thrombocytopenia (ITP)

To evaluate the safety and efficacy of Obinutuzumab in the treatment of pediatric primary immune thrombocytopenia in patients who have not responded adequately or relapsed after first-line glucocorticoid treatment.

12 - 18 years of age All Phase 2
Y Yunfei Chen, MD

A Prospective, One-arm and Open Clinical Study of Obinutuzumab in the Treatment of Immune Thrombocytopenia

To evaluate the safety and efficacy of Obinutuzumab in the treatment of immune thrombocytopenia in patients who have not responded adequately or relapsed after first-line treatment.

18 years of age All Phase 2
T Ting Sun, M.D

Anti-CD38 Antibody Treating Pediatric Primary Immune Thrombocytopenia (ITP)

To evaluate the safety and efficacy of Anti-CD38 Antibody in the treatment of pediatric primary immune thrombocytopenia in patients who have not responded adequately or relapsed after first-line treatment and at least one second-line therapy including Anti-CD20 Antibody and/or TPO-RA, or those in whom no other second-line treatment options are …

6 - 17 years of age All Phase 2

Simplify language using AI